Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is a clinical-stage biotechnology company with a diverse pipeline of novel treatments for autoimmune and inflammatory diseases, including those with significant unmet needs. With a focus on complex and chronic conditions, Zura Bio is developing innovative therapies that have the potential to improve treatment outcomes for a broad range of patients. With recent positive data readouts and ongoing development in key indications, the company is well-positioned for continued success and growth in the future.

Bears say

Zura Bio is facing significant risks to the attainment of its price target and rating due to potential clinical and regulatory failures of its lead programs, logistical challenges in drug manufacturing and shipment, and potential commercial challenges from current and future therapies. These risks are further compounded by the high expectations for the NEXUS-PMR study, which will begin in the next few years and will need to show significant efficacy and safety to meet its primary and secondary endpoints. Additionally, the trial's power for a delta of around 25% on the primary endpoint indicates the potential for disappointment if the results fall short of expectations.

ZURA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Strong Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Strong Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.